These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 22273839)

  • 1. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
    Pei SN; Ma MC; Wang MC; Kuo CY; Rau KM; Su CY; Chen CH
    Ann Hematol; 2012 Jul; 91(7):1007-12. PubMed ID: 22273839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
    Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
    J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
    Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
    J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
    Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
    Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [B-cell lymphoma developing de novo hepatitis B after salvage therapies including rituximab through seroconversion of surface antibody].
    Ishihara T; Kanagawa M; Koyama J; Hasegawa K; Suzuki T; Hirayama Y; Terui T
    Rinsho Ketsueki; 2014 Nov; 55(11):2283-7. PubMed ID: 25501408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
    J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
    Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
    Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
    Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.
    Zurawska U; Hicks LK; Woo G; Bell CM; Krahn M; Chan KK; Feld JJ
    J Clin Oncol; 2012 Sep; 30(26):3167-73. PubMed ID: 22711851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study.
    Hsu C; Tsou HH; Lin SJ; Wang MC; Yao M; Hwang WL; Kao WY; Chiu CF; Lin SF; Lin J; Chang CS; Tien HF; Liu TW; Chen PJ; Cheng AL;
    Hepatology; 2014 Jun; 59(6):2092-100. PubMed ID: 24002804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
    Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
    J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.
    Tsutsumi Y; Tanaka J; Kawamura T; Miura T; Kanamori H; Obara S; Asaka M; Imamura M; Masauzi N
    Ann Hematol; 2004 Jan; 83(1):58-60. PubMed ID: 14513286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
    Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
    Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients.
    Pei SN; Chen CH; Lee CM; Wang MC; Ma MC; Hu TH; Kuo CY
    Ann Hematol; 2010 Mar; 89(3):255-62. PubMed ID: 19697028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient.
    Feeney SA; McCaughey C; Watt AP; Agnaf MR; McDougall N; Wend UC; Gerlich WH; Coyle PV
    J Med Virol; 2013 Apr; 85(4):597-601. PubMed ID: 23359331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy.
    Nosotti L; D'Andrea M; Pitidis A; Pimpinelli F; Dessanti ML; Pisani F; Vignally P; Petti MC
    Scand J Infect Dis; 2012 Jan; 44(1):70-3. PubMed ID: 21905952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.